US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Lipidor publishes interim report for period 1 January - 30 September and Q3 2021

STOCKHOLM, Sweden, 25[th] November 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period July – September 2021. The quarterly report is available on the company's website (click here ) and in the attached pdf.Summary of the interim report – third quarter 2021 The quarter saw Lipidors most important milestone to date when we entered into an exclusive commercial agreement for registration, marketing, sales and distribution of AKP01 and AKP02 with RELIFE S.r.L. – part of the

Lipidor submits new patent application and expands collaboration with Cannassure using Lipidor’s AKVANO[®] technology for medicinal cannabis products

Stockholm, Sweden, 29 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the collaboration agreement with Cannassure Therapeutics has expanded to include a new patent family covering new innovative AKVANO[®] topical compositions. Lipidor submitted the new patent application to the European Patent Office on 25 October 2021.Earlier this year, Lipidor signed an exclusive licensing agreement with Cannassure Therapeutics for the use of Lipidor’s patented drug delivery technology AKVANO[® ]in topical medical cannabis products, and the programs are

Summer letter from Lipidor

STOCKHOLM, Sweden, 6 July 2021: CEO Ola Holmlund comments on the year’s progress so far and the recent commercial license agreement with the Menarini Group’s subsidiary RELIFE.The first half of this year has been an intensive period in several areas. In the beginning of the year, we signed a license agreement with Cannassure Therapeutics (for topical medical cannabis products based on Lipidor’s AKVANO® technology) as well as submitted an application regarding the start of the Phase III clinical trial with our combination drug candidate for the treatment of psoriasis (AKP02). Furthermore,

Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO[®] technology

STOCKHOLM, Sweden, 18 January 2021 – Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery technology AKVANO[®] in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions. Lipidor receives a royalty of 15-17.5% on

Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology

Stockholm, 30 September 2020 - Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collaboration with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the joint development agreement signed in December 2019, Cannassure has now announced that it intends to exercise its option and begin the

Lipidor presents updated project plan – initiates Phase III study of AKP02 in-house

In light of the company's successful Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and subsequent discussions with pharmaceutical companies, the Board of Lipidor submits an updated project plan together with prioritization of the company's project portfolio.In January 2020, Lipidor announced positive results from the completed Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis. Discussions with medium and large pharmaceutical companies regarding the licensing, marketing and sale of a product based on AKP01 have

Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products

Lipidor AB (“Lipidor”), a Swedish topical drug development company, and Cannassure Therapeutics Ltd (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, have today signed an agreement for the joint development of topical medical cannabis products commencing with evaluating the feasibility of incorporating active pharmaceutical ingredients (APIs) from the cannabis plant in Lipidor’s proprietary drug delivery platform technology AKVANO.Subject to a successful feasibility study, Cannassure has an option to enter an exclusive global license for the use

There are no items matching the current filter
There are no more items matching the current filter
Back to top